nach oben

Current Oncology Reports

Erschienen in:

01.08.2018 | Breast Cancer (B Overmoyer, Section Editor)

Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?

verfasst von: Narjust Duma, Kelly C. Gast, Grace M. Choong, Roberto A. Leon-Ferre, Ciara C. O’Sullivan

Erschienen in: Current Oncology Reports | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To provide an overview of the clinical development of poly(ADP-ribose) polymerase inhibitors (PARPi) in breast cancer to date and to review existing challenges and future research directions.

Recent Findings

We summarize the clinical development of PARPi in breast cancer from bench to bedside, and discuss the results of recent phase 3 trials in patients with metastatic breast cancer (MBC) and germline mutations in BRCA1/2 (gBRCAm). We will also provide an update regarding mechanisms of action and resistance to PARPi, and review clinical trials of PARPi as monotherapy or in combination regimens.

Summary

PARPi are a novel treatment approach in persons with gBRCA1/2m-associated MBC. Going forward, the clinical applicability of these compounds outside the gBRCAm setting will be studied in greater detail. The identification of accurate predictive biomarkers of response is a research priority.

Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20(7):1071–82. https://doi.org/10.1007/s10552-009-9331-1.CrossRefPubMedPubMedCentral

Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science. 2014;343(6178):1466–70. https://doi.org/10.1126/science.1251827.CrossRefPubMedPubMedCentral

Tun NM, Villani G, Ong K, Yoe L, Bo ZM. Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. Clin Genet. 2014;85(1):43–8. https://doi.org/10.1111/cge.12270.CrossRefPubMed

Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4):304–11. https://doi.org/10.1200/jco.2014.57.1414.CrossRefPubMed

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7. https://doi.org/10.1038/nature03443.CrossRefPubMed

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21. https://doi.org/10.1038/nature03445.CrossRefPubMed

Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Saura C, et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol. 2014;25(8):1656–63. https://doi.org/10.1093/annonc/mdu187.CrossRefPubMed

Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852–61. https://doi.org/10.1016/S1470-2045(11)70214-5.CrossRefPubMed

Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235–44. https://doi.org/10.1016/S0140-6736(10)60892-6.CrossRefPubMed

10.

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92. https://doi.org/10.1056/NEJMoa1105535.CrossRefPubMed

11.

Dizon DS. PARP inhibitors for targeted treatment in ovarian cancer. Lancet. 2017;390(10106):1929–30. https://doi.org/10.1016/S0140-6736(17)32418-2.CrossRefPubMed

12.

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–61. https://doi.org/10.1016/S0140-6736(17)32440-6.CrossRefPubMedPubMedCentral

13.

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34. https://doi.org/10.1056/NEJMoa0900212.CrossRefPubMed

14.

O'Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors. Front Oncol. 2014;4:42. https://doi.org/10.3389/fonc.2014.00042.PubMedPubMedCentralCrossRef

15.

•• Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–33. https://doi.org/10.1056/NEJMoa1706450. This was the phase 3 trial that led to the FDA approval of olaparib for gBRCAm-associated MBC. Patients in the olaparib arm had superior PFS outcomes (7.0 months vs. 4.2 months, p < 0.001) and fewer adverse events compared to the control group CrossRefPubMed

16.

FDA approves olaparib for germline BRCA-mutated metastatic breast cancer. FDA, www.fda.gov. 2018. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm592357.htm. Accessed 1/18/2018 2018.

17.

Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res. 2002;511(2):145–78.CrossRefPubMed

18.

Morales J, Li L, Fattah FJ, Dong Y, Bey EA, Patel M, et al. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr. 2014;24(1):15–28.CrossRefPubMedPubMedCentral

19.

Cerrato A, Morra F, Celetti A. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res. 2016;35(1):179. https://doi.org/10.1186/s13046-016-0456-2.CrossRefPubMedPubMedCentral

20.

O'Sullivan Coyne G, Chen AP, Meehan R, Doroshow JH. PARP inhibitors in reproductive system cancers: current use and developments. Drugs. 2017;77(2):113–30. https://doi.org/10.1007/s40265-016-0688-7.CrossRefPubMedPubMedCentral

21.

• Pommier Y, O'Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8(362):362ps17. https://doi.org/10.1126/scitranslmed.aaf9246. This article covers the importance of understanding the mechanisms of action of PARPi, especially PARP trapping, and the clinical relevance of the different mechanisms of action of different PARPi CrossRefPubMed

22.

Shen Y, Aoyagi-Scharber M, Wang B. Trapping poly(ADP-ribose) polymerase. J Pharmacol Exp Ther. 2015;353(3):446–57. https://doi.org/10.1124/jpet.114.222448.CrossRefPubMed

23.

Aguilar-Quesada R, Munoz-Gamez JA, Martin-Oliva D, Peralta A, Valenzuela MT, Matinez-Romero R, et al. Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition. BMC Mol Biol. 2007;8:29. https://doi.org/10.1186/1471-2199-8-29.CrossRefPubMedPubMedCentral

24.

Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25(1):32–40. https://doi.org/10.1093/annonc/mdt384.CrossRefPubMed

25.

Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–8. https://doi.org/10.1126/science.aam7344.CrossRefPubMedPubMedCentral

26.

Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10(4):293–301. https://doi.org/10.1038/nrc2812.CrossRefPubMedPubMedCentral

27.

Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15. https://doi.org/10.1038/nature10166.CrossRef

28.

Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4(10):814–9. https://doi.org/10.1038/nrc1457.CrossRefPubMed

29.

Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012;30(15):1879–87. https://doi.org/10.1200/JCO.2011.38.2010.CrossRefPubMed

30.

Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009;1(6–7):315–22. https://doi.org/10.1002/emmm.200900041.CrossRefPubMedPubMedCentral

31.

Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res. 2009;69(8):3589–96. https://doi.org/10.1158/0008-5472.CAN-08-4016.CrossRefPubMedPubMedCentral

32.

O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364(3):205–14. https://doi.org/10.1056/NEJMoa1011418.CrossRefPubMed

33.

Sinha G. Downfall of iniparib: a PARP inhibitor that doesn't inhibit PARP after all. J Natl Cancer Inst. 2014;106(1):djt447. https://doi.org/10.1093/jnci/djt447.CrossRefPubMed

34.

Yap TA, Sandhu SK, Carden CP, de Bono JS. Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin. 2011;61(1):31–49. https://doi.org/10.3322/caac.20095.CrossRefPubMed

35.

Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015;13:188. https://doi.org/10.1186/s12916-015-0425-1.CrossRefPubMedPubMedCentral

36.

O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014;32(34):3840–7. https://doi.org/10.1200/jco.2014.55.2984.CrossRefPubMed

37.

Yamamoto N, Nokihara H, Yamada Y, Goto Y, Tanioka M, Shibata T, et al. A phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci. 2012;103(3):504–9. https://doi.org/10.1111/j.1349-7006.2011.02179.x. CrossRefPubMedPubMedCentral

38.

Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140(2):199–203. https://doi.org/10.1016/j.ygyno.2015.12.020.CrossRefPubMed

39.

Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882–92. https://doi.org/10.1016/S1470-2045(13)70240-7.CrossRefPubMed

40.

de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov. 2017;7(6):620–9. https://doi.org/10.1158/2159-8290.CD-16-1250.CrossRefPubMedPubMedCentral

41.

Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer. 2016;114(7):723–30. https://doi.org/10.1038/bjc.2016.41.CrossRefPubMedPubMedCentral

42.

Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2013;15(5):R88. https://doi.org/10.1186/bcr3484.CrossRefPubMedPubMedCentral

43.

Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst. 2014;106(6):dju089. https://doi.org/10.1093/jnci/dju089.CrossRefPubMedPubMedCentral

44.

Han HS, Dieras V, Robson M, Palacova M, Marcom PK, Jager A, et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Ann Oncol. 2017;29:154–61. https://doi.org/10.1093/annonc/mdx505.CrossRefPubMedCentral

45.

Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, et al. Phase I study of veliparib (ABT-888) combined with cisplatin and vinorelbine in advanced triple-negative breast cancer and/or BRCA mutation-associated breast cancer. Clin Cancer Res. 2016;22(12):2855–64. https://doi.org/10.1158/1078-0432.CCR-15-2137.CrossRefPubMedPubMedCentral

46.

•• Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–50. https://doi.org/10.1200/jco.2014.56.2728. This was a phase 2 clinical trial of olaparib monotherapy for patients with solid tumors (breast, ovarian, pancreatic, and prostate cancer) associated with gBRCA1/2m . The tumor response rate in the breast cohort was 12.9% and stable disease was observed in 46.8% of breast cancer patients at 8 weeks. This study led to the design of breast cancer focused clinical trials of olaparib CrossRefPubMed

47.

Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012;2(11):1048–63. https://doi.org/10.1158/2159-8290.CD-11-0336.CrossRefPubMedPubMedCentral

48.

•• Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E-M et al. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). American Society of Clinical Oncology; 2017.This was a phase 2 trial of talazoparib in patients with gBRCAm -associated advanced or MBC, following platinum-based therapy or ≥ 3 platinum-free cytotoxic-based regimens. The ORR for gBRCA1m- and gBRCA2m- associated breast cancer was 24% and 34%, respectively. Most of the adverse events were hematologic in nature. This trial led to the design of the phase 3 trial of talazoparib in patients with gBRCAm -associated MBC.

49.

Tarapchak P. Investigational PARP inhibitor talazoparib shows clinical benefit in EMBRACA phase III trial. Oncology Times. 2017.

50.

Gourd K. San Antonio breast cancer symposium 2016. Lancet Oncol. 2017;18(2):176.CrossRefPubMed

51.

Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer immunology research. 2015.

52.

Huang J, Wang L, Cong Z, Amoozgar Z, Kiner E, Xing D, et al. The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1−/− murine model of ovarian cancer. Biochem Biophys Res Commun. 2015;463(4):551–6.CrossRefPubMed

53.

Tutt A, Ellis P, Kilburn L, Gilett C, Pinder S, Abraham J et al. Abstract S3-01: the TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). AACR; 2015.

54.

Robson M, Goessl C, Domchek S. Olaparib for metastatic germline BRCA-mutated breast cancer. N Engl J Med. 2017;377(18):1792–3. https://doi.org/10.1056/NEJMc1711644.CrossRefPubMed

55.

Sonnenblick A, de Azambuja E, Azim Jr HA, Piccart M. An update on PARP inhibitors—moving to the adjuvant setting. Nat Rev Clin Oncol. 2014;12:27–41. https://doi.org/10.1038/nrclinonc.2014.163.CrossRefPubMed

56.

Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. γH2AX and cancer. Nat Rev Cancer. 2008;8:957–67. https://doi.org/10.1038/nrc2523.CrossRefPubMedPubMedCentral

57.

Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137–54. https://doi.org/10.1158/2159-8290.CD-15-0714.CrossRefPubMedPubMedCentral

58.

Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol. 2013;229(3):422–9. https://doi.org/10.1002/path.4140.CrossRefPubMed

59.

Fojo T, Bates S. Mechanisms of resistance to PARP inhibitors—three and counting. Cancer Discov. 2013;3(1):20–3. https://doi.org/10.1158/2159-8290.cd-12-0514.CrossRefPubMedPubMedCentral

60.

Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 2013;3(1):68–81. https://doi.org/10.1158/2159-8290.cd-12-0049. CrossRefPubMed

61.

Wurzer G, Herceg Z, Wȩsierska-Gądek J. Increased resistance to anticancer therapy of mouse cells lacking the poly (ADP-ribose) polymerase attributable to up-regulation of the multidrug resistance gene product P-glycoprotein. Cancer Res. 2000;60(15):4238–44.PubMed

62.

Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012;12(9):587–98.CrossRefPubMed

63.

Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013;19:1381–8. https://doi.org/10.1038/nm.3369.CrossRefPubMed

64.

Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, et al. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res. 2013;19(19):5485–93. https://doi.org/10.1158/1078-0432.ccr-13-1262. CrossRefPubMed

65.

Ji J, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE, et al. Modeling pharmacodynamic response to the poly(ADP-ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells. PLoS One. 2011;6(10):e26152. https://doi.org/10.1371/journal.pone.0026152.CrossRefPubMedPubMedCentral

66.

Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 2014;16(6):475. https://doi.org/10.1186/s13058-014-0475-x.CrossRefPubMedPubMedCentral

67.

Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764–73. https://doi.org/10.1158/1078-0432.ccr-15-2477.CrossRefPubMedPubMedCentral

68.

Minckwitz GV, Timms K, Untch M, Elkin EP, Fasching PA, Schneeweiss A, et al. Prediction of pathological complete response (pCR) by homologous recombination deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: results from GeparSixto. J Clin Oncol. 2015;33(15_suppl):1004. https://doi.org/10.1200/jco.2015.33.15_suppl.1004.CrossRef

69.

Abkevich V, Timms K, Hennessy B, Potter J, Carey M, Meyer L, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107(10):1776–82.CrossRefPubMedPubMedCentral

70.

Stover EH, Konstantinopoulos PA, Matulonis UA, Swisher EM. Biomarkers of response and resistance to DNA repair targeted therapies. Clin Cancer Res. 2016;22(23):5651–60.CrossRefPubMed

71.

Balmaña J, Domchek SM, Tutt A, Garber JE. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov. 2011;1(1):29–34. https://doi.org/10.1158/2159-8274.cd-11-0048. CrossRefPubMed

72.

Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011;41(2):210–20. https://doi.org/10.1016/j.molcel.2010.12.005.CrossRefPubMed

73.

Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, et al. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle. 2012;11(20):3837–50. https://doi.org/10.4161/cc.22026.CrossRefPubMedPubMedCentral

Titel: Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
verfasst von: Narjust Duma
Kelly C. Gast
Grace M. Choong
Roberto A. Leon-Ferre
Ciara C. O’Sullivan
Publikationsdatum: 01.08.2018
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 8/2018
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-018-0709-7

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?